MUCOMMUNE

mucommune-logo

Mucommune is a privately-held preclinical stage company launched based on the “muco-trapping” monoclonal antibodies (mAb) platform developed at Johns Hopkins University and University of North Carolina at Chapel Hill.

#People #Financial #Website #More

MUCOMMUNE

Industry:
Biotechnology Pharmaceutical

Founded:
2015-01-01

Address:
Durham, North Carolina, United States

Country:
United States

Website Url:
http://www.mucommune.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
36.53 K USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Google Apps For Business Google GStatic Google Static Content Google Cloud


Current Employees Featured

samuel-lai_image

Samuel Lai
Samuel Lai Founder and CEO @ Mucommune
Founder and CEO
2016-01-01

Founder


samuel-lai_image

Samuel Lai

Investors List

one-north-carolina-small-business-program_image

One North Carolina Small Business Program

One North Carolina Small Business Program investment in Grant - Mucommune

Official Site Inspections

http://www.mucommune.com

  • Host name: unalocated.63.wixsite.com
  • IP address: 185.230.63.186
  • Location: Ashburn United States
  • Latitude: 39.018
  • Longitude: -77.539
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20147

Loading ...

More informations about "Mucommune"

Home | Mucommune

Mucommune is a professional R&D organization with a strong track record in advancing early-stage academic discoveries and inventions into IND-enabling preclinical studies and clinical …See details»

About Us - Mucommune

Mucommune is a privately-held R&D company. It was originally launched in 2016 based on the 'muco-trapping' monoclonal antibodies (mAb) platform developed at John Hopkins University …See details»

Technology & Platform | Mucommune

At the heart of Mucommune are world-class expertise in bioengineering, immunology, drug delivery, and mucosal biology that enables it to effectively advance diverse technologies into …See details»

Mucommune - Crunchbase Company Profile & Funding

Mucommune is a privately-held preclinical stage company launched based on the “muco-trapping” monoclonal antibodies (mAb) platform. View contacts for Mucommune to access new leads …See details»

Mucommune Company Profile 2024: Valuation, Funding

Developer of a monoclonal antibodies (mAb) platform intended to focus on the engineering of antibodies and biologics.See details»

Mucommune, LLC - BIO International Convention | BIO

Jun 6, 2023 · Mucommune is a privately-held startup focused on women's reproductive health. The lead product focuses on enabling non-hormonal contraception, in the form of anti-sperm …See details»

Mucommune LLC | North Carolina Biotech Center

Mucommune is developing a platform using monoclonal antibodies and mucus to reinforce the mucus barrier for female reproductive health. Company Location https://www.mucommune.comSee details»

Mucommune - LinkedIn

Advancing Innovations to Promote Female Reproductive Health | First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for …See details»

Sam Lai - Founder & Interim CEO at Mucommune - The Org

Dr. Sam Lai is a pharmacoengineering & molecular pharmaceutics professor at the University of North Carolina at Chapel Hill, and the founder of Mucommune. Lai's research interests include …See details»

Mucommune Is Newest Resident of UNC Eshelman Institute …

Mucommune, LLC, is the fourth company spun out of the research enterprise at the UNC Eshelman School of Pharmacy to take up residence in the Eshelman Institute for Innovation …See details»

UNC researchers developing mucus-trapping antibody tech to …

Jan 29, 2020 · Mucommune’s muco-trapping antibody technology enables antibodies – proteins in the immune system that fight intruders in the body – to immobilize viral and bacterial …See details»

Mucommune Receives Over $3M to Advance Muco-Trapping …

Mucommune LLC has been awarded over $3 million in five separate federal grants over the past several months to advance its muco-trapping antibody technology. The company was …See details»

Mucommune - Funding, Financials, Valuation & Investors

Mucommune is a privately-held preclinical stage company launched based on the “muco-trapping” monoclonal antibodies (mAb) platform.See details»

Careers | Mucommune

We are always seeking highly motivated individuals who strive to make a difference through science to join our team. The Mucommune team has broad in-house expertise in female …See details»

Mucommune - Tech Stack, Apps, Patents & Trademarks

Mucommune is a privately-held preclinical stage company launched based on the “muco-trapping” monoclonal antibodies (mAb) platform.See details»

Mucommune - VentureRadar

Mucommune is focused on harnessing IgG-mucin interactions to reinforce mucosal health against microbial infections. ... Find out more about Mucommune, Biotech and Biotechnology.See details»

Engineering monoclonal antibody-based contraception and …

Aug 4, 2020 · We are producing new antibody-based multipurpose prevention technology products to address these problems and fill an unmet need in female reproductive health.See details»

Publications - Mucommune

Contraceptive mAbs Shrestha B, Schaefer A, Chavez E, Kopp AJ, Jacobs TM, Moench TR, Lai SK. (2020) Engineering tetravalent IgGs with enhanced agglutination potencies for trapping …See details»

Delivery of pathogen-trapping antibodies for vaginal protection

Feb 10, 2016 · By enabling enhanced mAb function in mucus secretions, we expect Mucommune will help pave the way for improved, molecularly-targeted therapies and prophylaxis against a …See details»

Pipeline | Mucommune

MM008, Non-hormonal contraceptive IVR/Tablet. MM009, Bacterial vaginosis. PolyonSee details»

linkstock.net © 2022. All rights reserved